Furthermore, several monoclonal antibodies (HuMV833), small molecule VEGFR kinase inhibitors (SU5416, SU6668, SU11248, and ZD6474 in addition to soluble VEGF receptors (VEGF-Trap) and ribozymes (AngiozymeTM) have been investigated by various cancer therapy companies for their ability to inhibit VEGF or VEGFR in cancer therapy for AML [322]. This evidence concerns the gene VEGFA and acute myeloid leukemia.